Post-marketing surveillance, also known as pharmacovigilance, is the systematic monitoring of a drug’s safety after it has received regulatory approval and entered clinical use. Pre-approval clinical trials, while essential, are limited in their ability to detect rare adverse events, effects from long-term use, and interactions with other drugs or comorbidities. Post-marketing surveillance programs are designed to identify, assess, and respond to safety signals that emerge when a drug is used in large, diverse patient populations in real-world settings.
What Is Pharmacovigilance?
The World Health Organization defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Pharmacovigilance extends beyond adverse event reporting to encompass medication errors, substandard products, lack of efficacy, and drug abuse or misuse. The ultimate goals are to improve patient safety, inform regulatory decision-making, and promote the rational use of medicines. Pharmacovigilance is a legal obligation for marketing authorization holders in all major regulatory jurisdictions.
Spontaneous Reporting Systems
The cornerstone of pharmacovigilance is spontaneous reporting — the voluntary submission of adverse event reports by healthcare professionals, patients, and manufacturers. In the United States, the FDA Adverse Event Reporting System (FAERS) receives more than two million reports annually. In Europe, EudraVigilance collects reports for all centrally authorized products. Spontaneous reporting has the advantage of covering the entire marketed population at relatively low cost, but it suffers from underreporting — it is estimated that only 1 to 10 percent of adverse events are reported — and from the absence of a denominator, making incidence rate calculation impossible. Despite these limitations, spontaneous reporting remains the most important source of initial safety signals.
Risk Management Plans
A Risk Management Plan (RMP) is a regulatory document submitted at the time of marketing authorization that describes the drug’s safety profile, planned pharmacovigilance activities, and risk minimization measures. In the United States, the analogous document is the Risk Evaluation and Mitigation Strategy (REMS), which may include elements such as medication guides, communication plans, and restricted distribution programs. The RMP identifies important identified risks, important potential risks, and missing information, and specifies the pharmacovigilance activities needed to characterize each risk. Risk minimization measures range from routine labeling to additional interventions such as educational programs for prescribers or patient registries.
Post-Approval Safety Studies
Regulatory authorities may require post-approval safety studies (PASS in Europe) to investigate specific safety concerns identified during development or emerging after launch. These studies can be interventional clinical trials or observational studies using real-world data sources such as electronic health records, insurance claims databases, or patient registries. The Sentinel System in the United States and the ENCePP network in Europe provide infrastructure for conducting such studies using distributed data networks. Common study objectives include quantifying the incidence of rare adverse events, evaluating long-term safety in special populations, and assessing the effectiveness of risk minimization measures.
Signal Detection
Signal detection is the process of identifying potential causal associations between a drug and an adverse event that were not previously known. Statistical methods for signal detection include disproportionality analysis, which compares the proportion of reports for a specific drug-event combination to the proportion in the entire database. A signal is flagged when a drug-event pair is reported more frequently than expected relative to the background. Signal detection is performed continuously using up-to-date data from spontaneous reporting systems, literature surveillance, and other sources. Once a signal is identified, it undergoes signal validation (confirming the data quality and sufficient documentation) and signal prioritization (assessing the public health impact), followed by in-depth evaluation.
Regulatory Actions
When a safety signal is confirmed, regulatory authorities have a range of tools to manage the risk. The least disruptive action is labeling updates, such as adding a new warning, precaution, or adverse reaction to the prescribing information. More serious signals may lead to Dear Healthcare Professional communications (also called direct healthcare professional communications or DHPCs) to alert prescribers. In some cases, restrictions on use are imposed, such as limiting the indicated population, requiring specific monitoring, or establishing controlled distribution programs. For severe risks that cannot be adequately managed, the ultimate regulatory action is suspension or withdrawal of the marketing authorization. High-profile examples include the withdrawal of rofecoxib (Vioxx) for cardiovascular risk and rosiglitazone for cardiovascular concerns.
International Collaboration
Pharmacovigilance is inherently international because adverse events can occur anywhere a drug is used, and many drugs are marketed globally. The WHO’s Uppsala Monitoring Centre in Sweden maintains a global database of individual case safety reports from more than 150 member countries. The International Council for Harmonisation (ICH) guideline E2E on pharmacovigilance planning promotes standardization of safety data collection and reporting. Regional initiatives such as the European Union Network of competent authorities and the International Coalition of Medicines Regulatory Authorities (ICMRA) facilitate information sharing and coordinated action on emerging safety issues.
Conclusion
Post-marketing surveillance is a critical complement to pre-approval clinical trials in ensuring drug safety throughout a product’s lifecycle. The systems of spontaneous reporting, risk management planning, signal detection, and regulatory action form a comprehensive framework for identifying and managing risks that were not apparent at the time of approval. Effective pharmacovigilance requires collaboration among manufacturers, regulators, healthcare professionals, and patients to protect public health.
